Sandoz Sales Might Fall Short of Expectations, But Guidance Looks Safe — Market Talk

Sandoz Group's third-quarter sales might come in slightly below consensus expectations, but the Swiss maker of generic drugs is likely to reiterate its full-year guidance nevertheless, analysts at J.P. Morgan say in a research note. Third-quarter sales are expected to be just shy of the $3 billion…